Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells

Anti-Cancer Drug Design

Volumn 15, Issue 2, 2000, Pages 127-134

  Rappa, Germana ^a,b   Murren, John R ^a   Johnson, Liza Marie ^a   Lorico, Aurelio ^a,b   Sartorelli, Alan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Leukemia; MRP; Novobiocin; Ovarian carcinoma; VP 16

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; NOVOBIOCIN; TENIPOSIDE;

ARTICLE; BONE MARROW CELL; CELL MEMBRANE TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TRANSPORT; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ASCITES; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BONE MARROW; ETOPOSIDE; FEMALE; HUMANS; KINETICS; LEUKEMIA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NOVOBIOCIN; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0034047130     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Beck W.T. (1987) The cell biology of multiple drug resistance. Biochemical Pharmacology, 36, 2879.
2. Belinsky M.G., Bain L.J., Balsara B.B., Testa J.R., Kruh G.D. (1998) Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. Journal of the National Cancer Institute, 90, 1735.
3. Chabner B.A., Wilson W. (1991) Reversal of multidrug resistance. Journal of Clinical Oncology, 9, 4.
4. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M.V., Deeley R.G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650.
5. Drlica K., Franco R.J. (1988) Inhibition of DNA topoisomerases. Biochemistry, 27, 2253.
6. Eder J.P., Teicher B.A., Holden S.A., Cathcart K.N.S., Schnipper L.E. (1987) Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. Journal of Clinical Investigation, 79, 1524.
7. Eder J.P., Wheeler C.A., Teicher B.A., Schnipper L.E. (1991) A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Research, 51, 510.
8. Ellis G.K., Crowley J., Livingston R.B., Goodwin J.W., Hutchins L., Allen A. (1991) Cisplatin and novobiocin in the treatment of non-small-cell lung cancer. A Southwest Oncology Group Study. Cancer, 67, 2969.
9. Endicott J.A., Ling V. (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual Review of Biochemistry, 58, 131.
10. Gellert M. (1981) DNA topoisomerases. Annual Review of Biochemistry, 50, 879.
11. Grant C.E., Hipfner D.R., Valdimarrson G., Almquist K.C., Cole S.P.C., Deeley R.G. (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Research, 54, 357.
12. Ishikawa T. (1992) The ATP-dependent glutathione-S-conjugate export pump. Trends in Biochemical Science, 17, 463.
13. Jedlitschky G., Leier I., Buchholz U., Barnouin K., Kurz G., Keppler D. (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Research, 56, 988.
14. Jones R.D., Kerr D.J., Harnett A.N., Rankin E.M., Ray S., Kaye S.B. (1990) A pilot study of quinidine and epirubicin in the treatment of advancec breast cancer. British Journal of Cancer, 62, 133.
15. Kennedy M.J., Armstrong D.K., Huelskamp A., Ohly K., Clarke B.V., Colvin O.M., Grochow B., Chen T.-L., Davidson N.E. (1995) Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. Journal of Clinical Oncology 13, 1136.
16. Kohn K.W., Pommier Y., Kerrigan D., Markovitz J., Covey J.M. (1987) Topoisomerase II as a target of anticancer drug action in mammalian cells. National Cancer Institute Monographs, 4, 61.
17. Kool M., De Haas M., Scheffer G.L., Scheper R.J., Van Eijk M.J., Juijn J.A., Baas F., Borst P. (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Research, 57, 3537.
18. Kool M., Van Der Linden M., De Haas M., Baas F., Borst P. (1999) Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Research, 59, 175.
19. Liu L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry, 58, 351.
20. + leukemia cells. International Journal of Cancer, 52, 903.
21. Lorico A., Rappa G., Srimatkandada S., Catapano C.V., Fernandes D.J., Germino J.F., Sartorelli A.C. (1995) Increased rate of adenosine triphosphate-dependent etoposide (VP 16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Research, 55, 4352.
22. Lorico A., Rappa G., Flavell R.A., Sartorelli A.C. (1996) Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Research, 56, 5351.
23. Lorico A., Rappa G., Finch R.A., Yang D., Flavell R.A., Sartorelli A.C. (1997) Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Research, 57, 5238.
24. Miller T.P., Grogan T.M., Dalton W.S., Spier C.M., Scheper R.J., Salmon S.E. (1990) P-Glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology, 9, 17.
25. O'Dwyer P.J., Leyland-Jones B., Alonso M.T., Marsoni S., Wittes R.E. (1985) Drug therapy. Etoposide (VP-16-213). Current status of an active anticancer drug. New England Journal of Medicine, 312, 692.
26. Rappa G., Lorico A., Sartorelli A.C. (1992) Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). International Journal of Cancer, 51, 780.
27. Rappa G., Lorico A., Sartorelli A.C. (1993) Reversal of etoposide resistance in non P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Cancer Research, 53, 5487.
28. Rappa G., Lorico A., Flavell R.A., Sartorelli A.C. (1997) Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Research, 57, 5232.
29. Reizenstein P. (1990) Can verapamil induce second response in patients refractory to vincristine? Anticancer Research, 10, 955.
30. Sonneveld P., Nooter K. (1990) Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. British Journal of Haematology, 75, 208.
31. Stride B.D., Valdimarsson G., Gerlach J.H., Wilson G., Cole S.P.C., Deeley R.G. (1996) Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Molecular Pharmacology, 49, 962.
32. Wijnholds J., Evers R., Van Leusden M.R., Mol C.A., Zaman G.J., Mayer U., Beijnen J.H., Van Der Valk M., Krimpenfort P., Borst P. (1997) Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug-resistance associated protein. Nature Medicine, 3, 1275.
33. Zaman G.J.R., Flens M.J., Van Leusden M.R., De Haas M., Mulder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxterman H.J., Borst P. (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proceedings of the National Academy of Sciences, USA, 91, 8822.